Skip to main content

Table 1 Patient demographic and medical information

From: The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms

 

TP group

um-PEA-TP group

Age (mean ± S.D.)

64.1 ± 4.79

64.7 ± 4.12

Gender

5 (M) 20 (F)

9 (M) 21 (F)

Body weight (Kg -mean ± S.D.)

75.3 ± 13.7

77 ± 11.5

Height (cm -mean ± S.D.)

165 ± 5.5

162 ± 7.5

Caucasian (%)

100

100

Comorbidities (%):

diabetes mellitus type II

40

40

hypertension

28

20

ischemic heart disease

20

13.3

dyslipidemia

12

0

morbid obesity

16

20

diverticular disease of the colon

8

3.3

chronic obstructive pulmonary disease

36

33.3

heart rhythm disturbances

4

3.3

osteoporosis

48

43.3

obstructive arterial disease

4

0

chronic venous insufficiency of the lower limbs

4

23.3*

  1. *p < 0.05